COX7A2 and esophageal adenocarcinoma: Proteomic expression profiling reveals reduction of COX7A2 (cytochrome c oxidase subunit 7A2), a subunit of ETC complex IV, which is related to patients with esophageal adenocarcinoma who respond to cisplatin plus 5-Fu therapy.